

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Cancelled)

2. (Currently Amended) An isolated polypeptide consisting of comprising an amino acid sequence selected from the group consisting of:

~~(a) sequences encoded by a polynucleotide of claim 1; and~~

~~(b) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1; and~~

~~(c) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1;~~

~~(d) sequences set forth in SEQ ID NOS:241, 332-336, 342-346, 391-395, and 409-413;~~

~~(e) sequences having at least 70% identity to a sequence set forth in SEQ ID NOS:241, 332-336, 342-346, 391-395, and 404-413; and~~

~~(f)(a) sequences having at least 90% identity to a sequence set forth in SEQ ID NOS:241, 332-336, 342-346, 391-395, and 404-413;.~~

3.-10. (Cancelled)

11. (Currently Amended) A composition comprising the polypeptide of claim 2 in combination with a pharmaceutically acceptable carrier or excipient, a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

~~(a) polypeptides according to claim 2;~~

- (b) ~~polynucleotides according to claim 1;~~
- (e) ~~antibodies according to claim 5;~~
- (d) ~~fusion proteins according to claim 7;~~
- (e) ~~T cell populations according to claim 10; and~~
- (f) ~~antigen presenting cells that express a polypeptide according to claim 2.~~

12.-17. (Cancelled)

18. (Currently Amended) A composition comprising a ~~WT1~~—polypeptide according to claim 2 resuspended in a buffer comprising at least one sugar selected from the group consisting of trehalose, maltose, sucrose, fructose, and glucose, at a concentration of between about 7 and about 13 %.

19. (Original) The composition of claim 18 wherein said concentration is between about 8 and about 12%.

20. (Original) The composition of claim 18 wherein said concentration is about 10%.

21. (Currently Amended) A composition comprising a ~~WT1~~—polypeptide according to claim 2 resuspended in a buffer comprising at least 2 sugars selected from the group consisting of trehalose, maltose, sucrose, fructose, and glucose, at a concentration of between about 7 and about 13 %.

22. (Original) The composition of claim 21 wherein said concentration is between about 8 and about 12%.

23. (Original) The composition of claim 21 wherein said concentration is about 10%.

24. (Currently Amended) A composition comprising a WT1-polypeptide according to claim 2 resuspended in a buffer comprising at least 3 sugars selected from the group consisting of trehalose, maltose, sucrose, fructose, and glucose, at a concentration of between about 7 and about 13 %.

25. (Original) The composition of claim 24 wherein said concentration is between about 8 and about 12%.

26. (Original) The composition of claim 24 wherein said concentration is about 10%.

27. (Currently Amended) A composition comprising a WT1-polypeptide according to claim 2 resuspended in a buffer comprising:

- (a) at least one sugar selected from the group consisting of trehalose, maltose, sucrose, fructose, and glucose, at a concentration of between about 7 and about 13 %;
- (b) ethanolamine;
- (c) cysteine; and
- (d) Polysorbate-80.

28. (Original) The composition of claim 27 wherein said concentration is between about 8 and about 12%.

29. (Original) The composition of claim 27 wherein said concentration is about 10%.

30. (Cancelled)

31. (Currently Amended) A composition comprising a WT1-polypeptide according to claim 2 and MPL-SE.

32. (Cancelled)

33. (Currently Amended) A composition comprising a WT1-polypeptide according to claim 2 and Enhanzyn.

34. (Cancelled)

35. (New) A composition comprising the polypeptide of claim 2 in combination with a non-specific immune response enhancer.

36. (New) The composition according to claim 35 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

37. (New) The composition according to claim 35, wherein the immune response enhancer comprises a microsphere.